Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

271 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immune-Related Adverse Events and Corticosteroid Use for Cancer-Related Symptoms Are Associated With Efficacy in Patients With Non-small Cell Lung Cancer Receiving Anti-PD-(L)1 Blockade Agents.
Riudavets M, Mosquera J, Garcia-Campelo R, Serra J, Anguera G, Gallardo P, Sullivan I, Barba A, Del Carpio L, Barnadas A, Gich I, Majem M. Riudavets M, et al. Among authors: barba a. Front Oncol. 2020 Sep 7;10:1677. doi: 10.3389/fonc.2020.01677. eCollection 2020. Front Oncol. 2020. PMID: 33014837 Free PMC article.
Circulating leukocyte-platelet complexes as a predictive biomarker for the development of immune-related adverse events in advanced non-small cell lung cancer patients receiving anti-PD-(L)1 blocking agents.
Zamora C, Riudavets M, Anguera G, Alserawan L, Sullivan I, Barba A, Serra J, Ortiz MA, Gallardo P, Perea L, Gavira J, Barnadas A, Majem M, Vidal S. Zamora C, et al. Among authors: barba a. Cancer Immunol Immunother. 2021 Jun;70(6):1691-1704. doi: 10.1007/s00262-020-02793-4. Epub 2021 Jan 2. Cancer Immunol Immunother. 2021. PMID: 33388994 Free PMC article.
Antibiotic-exposed patients with non-small-cell lung cancer preserve efficacy outcomes following first-line chemo-immunotherapy.
Cortellini A, Ricciuti B, Facchinetti F, Alessi JVM, Venkatraman D, Dall'Olio FG, Cravero P, Vaz VR, Ottaviani D, Majem M, Piedra A, Sullivan I, Lee KA, Lamberti G, Hussain N, Clark J, Bolina A, Barba A, Benitez JC, Gorría T, Mezquita L, Hoton D, Aboubakar Nana F, Besse B, Awad MM, Pinato DJ. Cortellini A, et al. Among authors: barba a. Ann Oncol. 2021 Nov;32(11):1391-1399. doi: 10.1016/j.annonc.2021.08.1744. Epub 2021 Aug 13. Ann Oncol. 2021. PMID: 34400292 Free article.
Malignant Pleural Effusion: A Multidisciplinary Approach.
Pardessus Otero A, Rafecas-Codern A, Porcel JM, Serra-Mitjà P, Ferreiro L, Botana-Rial M, Ramos-Hernández C, Brenes JM, Canales L, Camacho V, Romero-Romero B, Trujillo JC, Martinez E, Cases E, Barba A, Majem M, Güell E, Pajares V. Pardessus Otero A, et al. Among authors: barba a. Open Respir Arch. 2024 Jun 19;6(4):100349. doi: 10.1016/j.opresp.2024.100349. eCollection 2024 Oct-Dec. Open Respir Arch. 2024. PMID: 39091982 Free PMC article. Review.
Eftilagimod Alpha (a Soluble LAG-3 Protein) Combined With Pembrolizumab in Second-Line Metastatic NSCLC Refractory to Anti-Programmed Cell Death Protein 1/Programmed Death-Ligand 1-Based Therapy: Final Results from a Phase 2 Study.
Krebs MG, Forster M, Majem M, Peguero J, Iams W, Clay T, Roxburgh P, Doger B, Bajaj P, Barba A, Perera S, Mueller C, Triebel F. Krebs MG, et al. Among authors: barba a. JTO Clin Res Rep. 2024 Aug 30;5(11):100725. doi: 10.1016/j.jtocrr.2024.100725. eCollection 2024 Nov. JTO Clin Res Rep. 2024. PMID: 39403626 Free PMC article.
Pembrolizumab as first-line treatment for advanced NSCLC in older adults: A phase II clinical trial evaluating geriatric and quality-of-life outcomes.
Blanco R, Dómine M, González JL, Loutfi S, Alfaro J, Saldaña J, Rubio J, Campos B, Hidalgo J, Barba A, Márquez D, Martin M, Olaverri A, Nadal E. Blanco R, et al. Among authors: barba a. Lung Cancer. 2023 Sep;183:107318. doi: 10.1016/j.lungcan.2023.107318. Epub 2023 Aug 2. Lung Cancer. 2023. PMID: 37557022 Free article. Clinical Trial.
271 results